Adjuvant chemotherapy (AC) in stage IB non-small cell lung cancer (NSCLC): Long-term follow-up of Cancer and Leukemia Group B (CALGB) 9633
| Autor: | Gary M. Strauss, David H. Harpole, David J. Sugarbaker, Stephen L. Graziano, David W. Johnstone, Michael A. Maddaus, Xiaofei Wang, E. E. Vokes, Robert A. Kratzke, J. Crawford, Richard L. Schilsky, H. H. Gillenwater, Lin Gu, Elizabeth Johnson, Mark R. Green |
|---|---|
| Rok vydání: | 2011 |
| Předmět: | |
| Zdroj: | Journal of Clinical Oncology. 29:7015-7015 |
| ISSN: | 1527-7755 0732-183X |
| DOI: | 10.1200/jco.2011.29.15_suppl.7015 |
| Popis: | 7015 Background: The value of AC in stage IB NSCLC remains controversial. In 2004, preliminary results of CALGB 9633 demonstrated a statistically significant overall survival (OS) advantage for pts randomized to adjuvant paclitaxel and carboplatin in resected stage IB NSCLC. However, subsequent analyses failed to demonstrate a significant OS advantage for all pts, although an unplanned subset analysis did show improved OS in pts with tumor diameter ≥4 cm (JCO, 26:5043, 2008). This report provides updated OS for CALGB 9633. Moreover, because the new 2010 AJCC staging system does not recognize 4 cm as a cut point, we correlated results with subgroups incorporated in the new system. Methods: Resected stage IB pts were randomized to paclitaxel 200 mg/m2 and carboplatin AUC 6 q3wks X4 cycles or observation. OS was the primary endpoint. Because of slow accrual, the accrual target was reduced from 500 to 384 pts, providing 80% power using a 1-tail logrank with alpha=0.05. Results: Between 1996-2003, 344 pts were... |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|